These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 34297698)

  • 21. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
    Lee J; Kim B; Jung HA; La Choi Y; Sun JM
    Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.
    Wakita A; Motoyama S; Nanjo H; Sato Y; Yoshino K; Sasaki T; Kawakita Y; Liu J; Imai K; Saito H; Minamiya Y
    Anticancer Res; 2017 Mar; 37(3):1433-1441. PubMed ID: 28314315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study.
    Wang R; Wen S; Du X; Xia J; Hu B; Zhang Y; Zhou G; Jiang F; Lu X; Zhu M; Xu X; Shen B
    Cancer Med; 2024 Sep; 13(17):e70228. PubMed ID: 39275896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
    Tsutsumi S; Saeki H; Nakashima Y; Ito S; Oki E; Morita M; Oda Y; Okano S; Maehara Y
    Cancer Sci; 2017 Jun; 108(6):1119-1127. PubMed ID: 28294486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
    Sugawara K; Fukuda T; Murakami C; Oka D; Yoshii T; Amori G; Ishibashi K; Kobayashi Y; Hara H; Kanda H; Motoi N
    Cancer Sci; 2024 Aug; 115(8):2819-2830. PubMed ID: 38693726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
    Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
    J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and prognostic significance of long noncoding RNA AK001796 in esophageal squamous cell carcinoma.
    Zong MZ; Shao Q; An XS
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):181-186. PubMed ID: 30657559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
    Konno-Kumagai T; Fujishima F; Nakamura Y; Nakano T; Nagai T; Kamei T; Sasano H
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30085020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
    Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
    Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
    Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical impact of angiotensin-(1-7)/mitochondrial assembly receptor axis in esophageal squamous cell carcinoma patients receiving curative esophagectomy.
    Chen YH; Lu HI; Lo CM; Huang CC; Hsiao CC; Li SH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):310-318. PubMed ID: 31202501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma.
    Koga N; Hu Q; Sakai A; Takada K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Oki E; Oda Y; Mori M
    Cancer Sci; 2021 Aug; 112(8):3018-3028. PubMed ID: 34009732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.
    Duan J; Xie Y; Qu L; Wang L; Zhou S; Wang Y; Fan Z; Yang S; Jiao S
    J Immunother Cancer; 2018 Oct; 6(1):100. PubMed ID: 30285868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic values of STAT3 and HIF-1α in esophageal squamous cell carcinoma.
    Zhao X; Tang YP; Wang CY; Wu JX; Ye F
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3351-3357. PubMed ID: 31081089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
    Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
    JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
    Wang WT; Guo CQ; Cui GH; Zhao S
    World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.